Phase I, Open-label, Single Sequence, Two-Period Study to Evaluate the Effect of Tepotinib on P-Glycoprotein by Investigating the Pharmacokinetics of the P-Glycoprotein Probe Substrate Dabigatran Etexilate in Healthy Subjects

Trial Profile

Phase I, Open-label, Single Sequence, Two-Period Study to Evaluate the Effect of Tepotinib on P-Glycoprotein by Investigating the Pharmacokinetics of the P-Glycoprotein Probe Substrate Dabigatran Etexilate in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2018

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Tepotinib (Primary)
  • Indications Adenocarcinoma; Liver cancer; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 16 Jul 2018 Planned End Date changed from 20 Jul 2018 to 6 Aug 2018.
    • 16 Jul 2018 Planned primary completion date changed from 20 Jul 2018 to 6 Aug 2018.
    • 12 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top